Published in J Urol on November 01, 2004
Role of potassium ion channels in detrusor smooth muscle function and dysfunction. Nat Rev Urol (2011) 1.64
New tricks for old dogs: KCNQ expression and role in smooth muscle. Br J Pharmacol (2009) 1.32
Molecular and functional characterization of Kv7 K+ channel in murine gastrointestinal smooth muscles. Am J Physiol Gastrointest Liver Physiol (2009) 1.05
Voltage-gated K(+) channels sensitive to stromatoxin-1 regulate myogenic and neurogenic contractions of rat urinary bladder smooth muscle. Am J Physiol Regul Integr Comp Physiol (2010) 1.04
KCNQ currents and their contribution to resting membrane potential and the excitability of interstitial cells of Cajal from the guinea pig bladder. J Urol (2009) 0.96
Activation of voltage-gated KCNQ/Kv7 channels by anticonvulsant retigabine attenuates mechanical allodynia of inflammatory temporomandibular joint in rats. Mol Pain (2010) 0.94
One man's side effect is another man's therapeutic opportunity: targeting Kv7 channels in smooth muscle disorders. Br J Pharmacol (2013) 0.92
Functional expression of KCNQ (Kv7) channels in guinea pig bladder smooth muscle and their contribution to spontaneous activity. Br J Pharmacol (2013) 0.91
Molecular expression and pharmacological evidence for a functional role of kv7 channel subtypes in Guinea pig urinary bladder smooth muscle. PLoS One (2013) 0.90
Vasorelaxant effects of novel Kv 7.4 channel enhancers ML213 and NS15370. Br J Pharmacol (2014) 0.89
Ezogabine: a new angle on potassium gates. Epilepsy Curr (2011) 0.87
Management of overactive bladder. Nat Rev Urol (2010) 0.85
Emerging pharmacological targets in overactive bladder therapy: experimental and clinical evidences. Int Urogynecol J Pelvic Floor Dysfunct (2008) 0.82
Functional and molecular evidence for Kv7 channel subtypes in human detrusor from patients with and without bladder outflow obstruction. PLoS One (2015) 0.81
Profile of ezogabine (retigabine) and its potential as an adjunctive treatment for patients with partial-onset seizures. Neuropsychiatr Dis Treat (2011) 0.80
Clinical utility, safety, and tolerability of ezogabine (retigabine) in the treatment of epilepsy. Drug Healthc Patient Saf (2012) 0.80
Ezogabine AKA Retigabine: Is More Better? Trying to Find the Right Dose From Clinical Trials. Epilepsy Curr (2012) 0.79
Investigation of the impact of urine handling procedures on interpretation of urinalysis findings and product safety in subjects treated with ezogabine. Ther Clin Risk Manag (2013) 0.79
Cardiovascular responses to retigabine in conscious rats--under normotensive and hypertensive conditions. Br J Pharmacol (2013) 0.79
New antiepileptic medication linked to blue discoloration of the skin and eyes. Ther Adv Drug Saf (2015) 0.76
The Novel KV7.2/KV7.3 Channel Opener ICA-069673 Reveals Subtype-Specific Functional Roles in Guinea Pig Detrusor Smooth Muscle Excitability and Contractility. J Pharmacol Exp Ther (2015) 0.75
Kv7 voltage-activated potassium channel inhibitors reduce fluid resuscitation requirements after hemorrhagic shock in rats. J Biomed Sci (2017) 0.75
KV7 channels in the human detrusor: channel modulator effects and gene and protein expression. Naunyn Schmiedebergs Arch Pharmacol (2016) 0.75
Urothelial signaling. Physiol Rev (2013) 2.56
Distribution and function of the hydrogen sulfide-sensitive TRPA1 ion channel in rat urinary bladder. Eur Urol (2007) 2.21
EAU guidelines on urinary incontinence. Eur Urol (2010) 2.10
Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol (2006) 1.94
Muscarinic receptor antagonists for overactive bladder. BJU Int (2007) 1.81
Summary of the recommendations on sexual dysfunctions in men. J Sex Med (2004) 1.78
Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain. Eur J Pain (2010) 1.77
A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature. Eur Urol (2009) 1.76
Partial outlet obstruction enhances modular autonomous activity in the isolated rat bladder. J Urol (2003) 1.75
(-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther (2007) 1.72
Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future. Eur Urol (2006) 1.61
Increased bladder activity is associated with elevated oxidative stress markers and proinflammatory cytokines in a rat model of atherosclerosis-induced chronic bladder ischemia. Neurourol Urodyn (2011) 1.60
Bladder dysfunction in a new mutant mouse model with increased superoxide--lack of nitric oxide? J Urol (2010) 1.58
Recent advances in understanding the biology of diabetes-associated bladder complications and novel therapy. BJU Int (2005) 1.56
Future direction in pharmacotherapy for non-neurogenic male lower urinary tract symptoms. Eur Urol (2013) 1.54
Urine derived cells are a potential source for urological tissue reconstruction. J Urol (2008) 1.54
Immunohistochemical distribution of cyclic GMP-dependent protein kinase-1 in human prostate tissue. Eur Urol (2007) 1.46
Mechanisms of action of botulinum neurotoxins, β3-adrenergic receptor agonists, and PDE5 inhibitors in modulating detrusor function in overactive bladders: ICI-RS 2011. Neurourol Urodyn (2012) 1.46
Smooth-muscle-specific gene transfer with the human maxi-k channel improves erectile function and enhances sexual behavior in atherosclerotic cynomolgus monkeys. Eur Urol (2008) 1.46
Effect of melatonin on chronic bladder-ischaemia-associated changes in rat bladder function. BJU Int (2013) 1.44
Presence of phosphodiesterase type 5 in the spinal cord and its involvement in bladder outflow obstruction related bladder overactivity. J Urol (2013) 1.43
Localization and function of cannabinoid receptors in the corpus cavernosum: basis for modulation of nitric oxide synthase nerve activity. Eur Urol (2009) 1.40
Protective effect of a β3-adrenoceptor agonist on bladder function in a rat model of chronic bladder ischemia. Eur Urol (2013) 1.39
Simultaneous registration of intraabdominal and intravesical pressures during cystometry in conscious rats--effects of bladder outlet obstruction and intravesical PGE2. Neurourol Urodyn (2008) 1.26
Bladder afferent signaling: recent findings. J Urol (2010) 1.25
Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur Urol (2011) 1.23
Human bladder as a novel target for vitamin D receptor ligands. J Clin Endocrinol Metab (2004) 1.22
Characterization of urine-derived stem cells obtained from upper urinary tract for use in cell-based urological tissue engineering. Tissue Eng Part A (2011) 1.21
A mutation in the inner mitochondrial membrane peptidase 2-like gene (Immp2l) affects mitochondrial function and impairs fertility in mice. Biol Reprod (2007) 1.20
Increased connexin43-mediated intercellular communication in a rat model of bladder overactivity in vivo. Am J Physiol Regul Integr Comp Physiol (2003) 1.19
Intravesical adenosine triphosphate stimulates the micturition reflex in awake, freely moving rats. J Urol (2002) 1.15
Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions? BJU Int (2006) 1.15
Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo. BJU Int (2008) 1.15
The role of the rhabdosphincter in female rat voiding. BJU Int (2004) 1.11
Detrusor responses to prostaglandin E2 and bladder outlet obstruction in wild-type and Ep1 receptor knockout mice. J Urol (2004) 1.09
Early stages of in situ bladder regeneration in a rodent model. Tissue Eng Part A (2010) 1.06
2-(3-Fluoro-4-methylsulfonylaminophenyl)propanamides as potent TRPV1 antagonists: structure activity relationships of the 2-oxy pyridine C-region. Eur J Med Chem (2013) 1.05
Substantial detrusor overactivity in conscious spontaneously hypertensive rats with hyperactive behaviour. Scand J Urol Nephrol (2009) 1.05
Phasic non-micturition contractions in the bladder of the anaesthetized and awake rat. BJU Int (2006) 1.04
Mechanistic and functional differentiation of tapentadol and tramadol. Expert Opin Pharmacother (2012) 1.04
Characterization of the early proliferative response of the rodent bladder to subtotal cystectomy: a unique model of mammalian organ regeneration. PLoS One (2012) 1.03
Tapentadol hydrochloride: a next-generation, centrally acting analgesic with two mechanisms of action in a single molecule. Drugs Today (Barc) (2009) 1.03
The effect of atherosclerosis-induced chronic bladder ischemia on bladder function in the rat. Neurourol Urodyn (2011) 1.03
Nicotinamide mononucleotide adenylyltransferase 2 (Nmnat2) regulates axon integrity in the mouse embryo. PLoS One (2012) 1.02
The role of corticotropin releasing factor and its antagonist, astressin, on micturition in the rat. Auton Neurosci (2005) 1.02
Effects of beta(3)-adrenoceptor stimulation on prostaglandin E(2)-induced bladder hyperactivity and on the cardiovascular system in conscious rats. Neurourol Urodyn (2002) 1.01
Melatonin restores impaired contractility in aged guinea pig urinary bladder. J Pineal Res (2008) 0.99
Cebranopadol: a novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist. J Pharmacol Exp Ther (2014) 0.99
Voiding pattern analysis as a surrogate for cystometric evaluation in uroplakin II knockout mice. J Urol (2008) 0.98
Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice. Eur J Pain (2005) 0.98
Effects of gamma-aminobutyrate B receptor modulation on normal micturition and oxyhemoglobin induced detrusor overactivity in female rats. J Urol (2002) 0.98
Researching bladder afferents-determining the effects of β(3) -adrenergic receptor agonists and botulinum toxin type-A. Neurourol Urodyn (2011) 0.98
Location of interstitial cells and neurotransmitters in the mouse bladder. BJU Int (2006) 0.97
Actions of tramadol on micturition in awake, freely moving rats. Br J Pharmacol (2003) 0.96
Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats. Proc Natl Acad Sci U S A (2004) 0.96
Cystometric findings in mice lacking muscarinic M2 or M3 receptors. J Urol (2004) 0.93
Transient receptor potential A1 (TRPA1) activity in the human urethra--evidence for a functional role for TRPA1 in the outflow region. Eur Urol (2008) 0.93
Effects of resiniferatoxin desensitization of capsaicin-sensitive afferents on detrusor over-activity induced by intravesical capsaicin, acetic acid or ATP in conscious rats. Naunyn Schmiedebergs Arch Pharmacol (2003) 0.93
Effects of selective beta2 and beta3-adrenoceptor agonists on detrusor hyperreflexia in conscious cerebral infarcted rats. J Urol (2002) 0.92
Long-term structural and functional effects of autologous muscle precursor cell therapy in a nonhuman primate model of urinary sphincter deficiency. J Urol (2013) 0.92
Common theme for drugs effective in overactive bladder treatment: inhibition of afferent signaling from the bladder. Int J Urol (2012) 0.92
Distribution and function of cannabinoid receptors 1 and 2 in the rat, monkey and human bladder. J Urol (2009) 0.92
Functional consequences of chronic bladder ischemia. Neurourol Urodyn (2013) 0.91
Expression of nitric oxide synthase immunoreactivity in the human female intramural striated urethral sphincter. J Urol (2003) 0.91
Morphology, phenotype and ultrastructure of fibroblastic cells from normal and neuropathic human detrusor: absence of myofibroblast characteristics. J Urol (2003) 0.91
β-Adrenergic receptor subtype expression in myocyte and non-myocyte cells in human female bladder. Cell Tissue Res (2010) 0.90
Phosphodiesterase 5 in the female pig and human urethra: morphological and functional aspects. BJU Int (2006) 0.90
Role of alpha1-adrenergic receptors in detrusor overactivity induced by cold stress in conscious rats. Neurourol Urodyn (2009) 0.89
Effects of cannabinor, a novel selective cannabinoid 2 receptor agonist, on bladder function in normal rats. Eur Urol (2010) 0.89
The novel β3-adrenoceptor agonist mirabegron reduces carbachol-induced contractile activity in detrusor tissue from patients with bladder outflow obstruction with or without detrusor overactivity. Eur J Pharmacol (2012) 0.89
Physiological and pharmacological aspects of the vas deferens-an update. Front Pharmacol (2013) 0.89
Selection of a control rat for conscious spontaneous hypertensive rats in studies of detrusor overactivity on the basis of measurement of intra-abdominal pressures. Neurourol Urodyn (2010) 0.89
Urodynamic effects of a novel EP(1) receptor antagonist in normal rats and rats with bladder outlet obstruction. J Urol (2007) 0.89
Persistent detrusor overactivity in rats after relief of partial urethral obstruction. Am J Physiol Regul Integr Comp Physiol (2011) 0.89
Effect of the SK/IK channel modulator 4,5-dichloro-1,3-diethyl-1,3-dihydro-benzoimidazol-2-one (NS4591) on contractile force in rat, pig and human detrusor smooth muscle. BJU Int (2011) 0.89
Impact of partial urethral obstruction on bladder function: time-dependent changes and functional correlates of altered expression of Ca²⁺ signaling regulators. Am J Physiol Renal Physiol (2012) 0.88
Relation between expression of α(1)-adrenoceptor mRNAs in bladder mucosa and urodynamic findings in men with lower urinary tract symptoms. Scand J Urol Nephrol (2010) 0.88
Signal transduction pathways of muscarinic receptor mediated activation in the newborn and adult mouse urinary bladder. BJU Int (2008) 0.88
Alterations in bladder function associated with urothelial defects in uroplakin II and IIIa knockout mice. Neurourol Urodyn (2009) 0.88
Effect of melatonin on age associated changes in Guinea pig bladder function. J Urol (2007) 0.88
Impaired bladder function in aging male rats. J Urol (2010) 0.88
Effects of NAD-299, a new, highly selective 5-HT1A receptor antagonist, on bladder function in rats. Naunyn Schmiedebergs Arch Pharmacol (2002) 0.87
A dose-dependent dual effect of oestrogen on voiding in the male mouse? BJU Int (2005) 0.87
Do the urinary bladder and large bowel interact, in sickness or in health? ICI-RS 2011. Neurourol Urodyn (2012) 0.87
Prophylactic effect of tadalafil on bladder function in a rat model of chronic bladder ischemia. J Urol (2012) 0.87
Effects of intravesical instillation of ATP on rat bladder primary afferent activity and its relationship with capsaicin-sensitivity. Neurourol Urodyn (2010) 0.86
Effects of tolterodine on afferent neurotransmission in normal and resiniferatoxin treated conscious rats. J Urol (2007) 0.86
Development of bladder dysfunction in a rat model of dopaminergic brain lesion. Neurourol Urodyn (2010) 0.86
Tramadol inhibits rat detrusor overactivity caused by dopamine receptor stimulation. J Urol (2003) 0.86
Presence of central nervous system, cardiovascular and overall co-morbidity burden in patients with overactive bladder disorder in a real-world setting. BJU Int (2011) 0.86
Rho-kinase and effects of Rho-kinase inhibition on the lower urinary tract. Neurourol Urodyn (2007) 0.86
Stem cell therapy ameliorates bladder dysfunction in an animal model of Parkinson disease. J Urol (2012) 0.85
Transmitters contributing to the voiding contraction in female rats. BJU Int (2004) 0.85
Vardenafil-induced relaxation and cyclic nucleotide levels in normal and obstructed rat urinary bladder. BJU Int (2009) 0.85
Terminology, epidemiology, etiology, and pathophysiology of nocturia. Neurourol Urodyn (2014) 0.84
Interactions between cGMP- and cAMP-pathways are involved in the regulation of penile smooth muscle tone. World J Urol (2004) 0.84
Chronic bladder ischemia and oxidative stress: new pharmacotherapeutic targets for lower urinary tract symptoms. Int J Urol (2014) 0.84